Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. - Wikidata - wikimedia - TriplyDB

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

http://www.wikidata.org/entity/Q43194107

about

DPP4 in Diabetes DPP-4 inhibition and islet function Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy.Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial.Practical Application of Antidiabetic Efficacy of Lycium barbarum Polysaccharide in Patients with Type 2 Diabetes.Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes.Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation.Profile of vildagliptin in type 2 diabetes: efficacy, safety, and patient acceptability.Efficacy and safety of combination therapy with vildagliptin and metformin versus metformin up-titration in Chinese patients with type 2 diabetes mellitus: study design and rationale of the vision study Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial Exercise therapy in type 2 diabetes.Vildagliptin in clinical practice: a review of literature.A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus.Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans.From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.The alpha-cell as target for type 2 diabetes therapy.Clinical pharmacokinetics and pharmacodynamics of vildagliptin.Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.Do we know the true mechanism of action of the DPP-4 inhibitors?C-Peptide Levels Predict the Effectiveness of Dipeptidyl Peptidase-4 Inhibitor Therapy Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 diabetes.Safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin and low-dose metformin.Assessment of beta-cell function in young patients with type 2 diabetes: arginine-stimulated insulin secretion may reflect beta-cell reserve.Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study.Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice.Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.Latent Autoimmune Diabetes in Adults: Current Status and New Horizons.

P2860

Q26797335-60C51E1E-1D85-4630-B9E8-5E17D59D7E8E Q27028127-48C4433B-6146-43A4-9DDC-AEDB95A32F9E Q33626226-E60A8BEF-5D97-43B1-A416-A76172D1C7BA Q34004470-64B8990B-E752-478E-8CEE-510C389C6F73 Q35026483-31B1C85C-8A48-4B8D-B203-51E850D6355D Q35091620-518F4A35-6ACB-4630-89EF-173A54E899DB Q35763816-8CBC5E26-4333-4987-AE82-0D5E0E9262F2 Q35928257-2CA067D8-2FF0-498D-B9AB-CE2F30BDCA06 Q36628919-258B20DB-EC89-4C62-8ECB-03A048E2AE78 Q36758200-983F2914-F486-4C18-9A7F-F9FCF90F8625 Q36960161-E7DE9E49-17E5-450A-B084-C3BF2D39BF92 Q37153711-E9947CFE-9950-42E6-B9E9-998F55864BB0 Q37316259-BDC6C6BA-0723-48AC-90AF-4CE40515B9A9 Q37348976-5DD4187F-0378-4E38-BBDF-EFED4F1C47AF Q37412024-DBDEAF7E-74DE-47A7-996B-D3D0354110F5 Q37623831-307E99DB-1C6F-4724-91ED-DF4542D89DF1 Q37652091-70E9CD1D-DAF1-455E-8141-8C2960CE81E8 Q37867193-2A783767-EBB2-495F-9EE4-49040655017A Q37900151-D8E2A0ED-7FC5-4D0D-8A53-D8B6C1BB1EFA Q37900690-8A8F8163-7AA9-4702-AC54-BF716918E85D Q37977335-25862CFA-B5B6-4490-B66E-E55D2987FCFE Q37984567-5EEDFC6A-94C4-4B88-A383-032E7AEEEADB Q38106411-D6765BB4-32EE-4512-A0AD-C7235BC9BC52 Q38682317-C41476C9-EA54-4F03-B3DF-99D3174BB3D2 Q39329866-C43E87F6-2A7F-451E-8DF7-82F46675AF81 Q42368200-7C701A22-3642-4EF2-9005-A16F3B726244 Q45985301-2E83F73D-28BF-4053-B46B-5B20A322DEA8 Q49991307-6AACA914-09AE-429A-B231-65258474AC87 Q51327644-65476FAB-AB83-4158-8070-437D84BA8E25 Q51349530-7D1E2ACF-5D6C-4220-ACFC-CAB3258C18F5 Q51377185-ED247868-4E21-4037-8374-D63AB1B5CC72 Q51381989-43756FAB-BB90-498D-A9F3-3070817722DF Q55397117-20B49CF7-D2D9-47A4-8D17-B3CEA41D05D4

P2860

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

http://www.wikidata.org/entity/Q43194107

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Treatment with the dipeptidyl ...... subjects with type 2 diabetes.

@en

Treatment with the dipeptidyl ...... subjects with type 2 diabetes.

@nl

type

label

Treatment with the dipeptidyl ...... subjects with type 2 diabetes.

@en

Treatment with the dipeptidyl ...... subjects with type 2 diabetes.

@nl

prefLabel

Treatment with the dipeptidyl ...... subjects with type 2 diabetes.

@en

Treatment with the dipeptidyl ...... subjects with type 2 diabetes.

@nl

P1433

Q43194107-C5CE2679-1EFC-45A6-A30F-5B41651BFC66

P1476

Q43194107-25674AAF-E26F-4428-8CF3-A7E76D863D4A

P2093

Q43194107-151B5423-E1C0-4AB5-AA9B-EC7DB80EEF60

Q43194107-2BA97E29-92F4-4BA9-BFA8-8C11387337A2

Q43194107-4BEE99AD-836F-4A22-8A9B-A12E1F964951

Q43194107-508852FE-F7FC-493E-83E9-BAB51C06F41F

Q43194107-5BC2BCFF-8087-44CD-BD95-3EFA6054B3DF

Q43194107-9B478EDF-BB89-443C-A613-6A5DAD974E95

Q43194107-AAD1BBFB-D48C-4992-BDFB-00D5EFD52909

Q43194107-AFB8C3C6-6360-4FB1-8D77-400FE36A78F7

Q43194107-B8753E7E-6BD2-4647-A62B-DD396E155FE4

Q43194107-D05DFBB7-7823-43D7-A627-33D194EF1BE8

P2860

Q43194107-0380E40F-D470-4550-9A31-1C567B051EE2

Q43194107-04BE51DE-E85B-4F12-BAF5-ED8377756910

Q43194107-0FF7A607-C70A-46CF-8623-ED58FCD5ABD2

Q43194107-10FFD172-8B0F-4AD0-8765-EB9C5F5ED22A

Q43194107-142A5F76-B944-4C7F-8C32-88CF32363666

Q43194107-1F9BCFAA-7403-4F43-8F14-29C905CFE111

Q43194107-2E8CC6FD-AB5A-4FC2-B1B1-F1250B9C0CD9

Q43194107-2EA2083A-11C9-4A4C-8D8D-DD896CBE3748

Q43194107-40732FF3-3BAF-4DAA-8984-E4DD0A3BF65B

Q43194107-50C39798-D572-4AD8-855E-05E5D7199D15

P304

Q43194107-F5C1294F-5A3D-4038-8E7C-B32C93F2E908

P31

Q43194107-D484E219-C159-4B85-813C-691F1BC7BF00

P356

Q43194107-274F66B2-09FC-4157-AE77-DD63C885FCA0

P407

Q43194107-D425FF82-5165-4F3E-808E-C6D8E7506222

P433

Q43194107-79AD6242-576B-48EF-9F12-4B5BE5A3EB33

P478

Q43194107-0500C978-8563-439C-8BA6-C1293F630D96

P577

Q43194107-E4D9EE86-5770-4941-B51C-CC8FC1DB8B77

P5875

Q43194107-ABF0C3DF-1802-4751-83E5-7D4D247C0B69

P698

Q43194107-97C75ED0-02C3-4091-B11C-1E43F66CED98

P921

Q43194107-6654C4F8-1A39-4476-98B3-3FF8C45B4B1F

P932

Q43194107-AA8D1A51-0A03-42B6-AA9B-CE12838B8D0F

P356

P1433

The Journal of Clinical Endocrinology and Metabolism

P1476

Treatment with the dipeptidyl ...... subjects with type 2 diabetes.

@en

P2093

Amanda M Denney

http://www.w3.org/2001/XMLSchema#string

Beth E Dunning

http://www.w3.org/2001/XMLSchema#string

David A D'Alessio

http://www.w3.org/2001/XMLSchema#string

James E Foley

http://www.w3.org/2001/XMLSchema#string

Julie M Martin

http://www.w3.org/2001/XMLSchema#string

Linda M Hermiller

http://www.w3.org/2001/XMLSchema#string

Monica Liqueros Saylan

http://www.w3.org/2001/XMLSchema#string

Richard E Pratley

http://www.w3.org/2001/XMLSchema#string

Ronald L Prigeon

http://www.w3.org/2001/XMLSchema#string

William G Tharp

http://www.w3.org/2001/XMLSchema#string

P2860

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

Biology of incretins: GLP-1 and GIP

Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications.

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans.

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.

Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.

The biology of incretin hormones.

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.

P304

81-88

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/JC.2008-1135

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23425202

http://www.w3.org/2001/XMLSchema#string

P698

18957505

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

P932

2630874

http://www.w3.org/2001/XMLSchema#string